DXCM
$79.28
Dexcom
($1.49)
(1.84%)
DXCM
Earnings Whisper ®
N/A
3rd Quarter September 2025
Consensus:  $0.56
Revenue:  $1.18 Bil
Wednesday
Oct 29
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Wednesday, July 30, 2025

What do you expect when DXCM reports earnings?
Beat
Meet
Miss

Where is DXCM's stock price going from here?
Up
Flat
Down
Stock chart of DXCM
Analysts
Summary of analysts' recommendations for DXCM
Score
Grade
Pivots
Resistance
$82.38
$81.62
$80.45

$79.69

Support
$78.52
$77.76
$76.59
Tweet
Growth
Description
DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.
Peers
Boston ScientificStrykerAbbottWatersResMedBecton, Dickinson3MBaxter InternationalWest Pharmaceutical ServicesTeleflex